Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Granulomatous Vasculitis
Conditions
Eosinophilic Granulomatous Vasculitis
Trial Timeline
Oct 29, 2019 → Mar 31, 2026
NCT ID
NCT04157348About Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab
Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab is a phase 3 stage product being developed by AstraZeneca for Eosinophilic Granulomatous Vasculitis. The current trial status is active. This product is registered under clinical trial identifier NCT04157348. Target conditions include Eosinophilic Granulomatous Vasculitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04157348 | Phase 3 | Active |
Competing Products
20 competing products in Eosinophilic Granulomatous Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| benralizumab + benralizumab + Placebo | Kyowa Kirin | Phase 2 | 52 |
| SHR-1703 + SHR-1703 Placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| NS-229 + Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Esomeprazole + Budesonide | AstraZeneca | Phase 2/3 | 65 |
| Tezepelumab + Tezepelumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Approved | 85 |
| Cohort | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Matching placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab Prefilled Syringe | AstraZeneca | Approved | 85 |
| benralizumab | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Tezepelumab + Placebo | AstraZeneca | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 2/3 | 65 |
| inhaled/swallowed budesonide + viscous/swallowed budesonide | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + 129 Xenon | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |